Peginterferon Alfa-2b-100mcg/180mcg
Basic Info
Model No.: Peginterferon 00034
Product Description
Model NO.: Peginterferon 00034 Specifications: 100mcg/180mcg Stadard: GMP Trademark: Arrow (New Zealand) Specification: GMP COA HS Code: 30049090 Product Name: Peginterferon Alfa-2b-100mcg/180mcg Package.: 1vial + 1AMP + Syringe/Box Registration: Documents and Samples Can Be Provided Transport Package: 5 Ampoules/ Tray/Box Origin: China Peginterferon alfa-2b-100mcg/180mcg
1,Product name:Peginterferon alfa-2b-100mcg/180mcg
2.Specification:100mcg/180mcg
3.Package:1vials +1amp+ syringe/box
4.Shelf life:36 months
5.Standard: GMP
6. Registration documents and samples can be provided.
7. Good quality and competitive price.
It has been approved as treatment for melanoma with nodal involvement after surgical resection in April 2011.
PEG-interferon alpha is a pegylated interferon composed of 165 amino acids. The PEG (polyethylene glycol) protects the molecule from proteolytic breakdown and increases the biological half-life of the interferon protein.
It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.
Mechanism of action
One of the major mechanisms of PEG-interferon alpha-2b utilizes the JAK-STAT signaling pathway. The basic mechanism works such that PEG-interferon alpha-2b will bind to its receptor, interferon-alpha receptor 1 and 2 (IFNAR1/2). Upon ligand binding the Tyk2 protein associated with IFNAR1 is phosphorylated which in turn phosphorylates Jak1 associated with IFNAR2. This kinase continues its signal transduction by phosphorylation of signal transducer and activator of transcription (STAT) 1 and 2 via Jak 1 and Tyk2 respectively. The phosphorylated STATs then dissociate from the receptor heterodimer and form an interferon transcription factor with p48 and IRF9 to form the interferon stimulate transcription factor-3 (ISGF3). This transcription factor then translocates to the nucleus where it will transcribe several genes involved in cell cycle control, cell differentiation, apoptosis, and immune response.
PEG-interferon alpha-2b acts as a multifunctional immunoregulatory cytokine by transcribing several genes, including interleukin 4 (IL4). This cytokine is responsible for inducing T helper cells to become type 2 helper T cells. This ultimately results in the stimulation of B cells to proliferate and increase their antibody production. This ultimately allows for an immune response, as the B cells will help to signal the immune system that a foreign antigen is present.
Another major mechanism of type I interferon alpha (IFNα) is to stimulate apoptosis in malignant cell lines. Previous studies have shown that IFNα can cause cell cycle arrest in U266, Daudi, and Rhek-1 cell lines.
A follow-up study researched to determine if the caspases were involved in the apoptosis seen in the previous study as well as to determine the role of mitochondrial cytochrome c release. The study confirmed that there was cleavage of caspase-3, -8, and -9. All three of these cysteine proteases play an important role in the initiation and activation of the apoptotic cascade. Furthermore, it was shown that IFNα induced a loss in the mitochondrial membrane potential which resulted in the release of cytochrome c from the mitochondria. Follow-up research is currently being conducted to determine the upstream activators of the apoptotic pathway that are induced by IFNα
Host genetic factors influencing treatment response
For genotype 1 hepatitis C treated with pegylated interferon-alfa-2a or pegylated interferon-alfa-2b combined with ribavirin, it has been shown that genetic polymorphisms near the human IL28B gene, encoding interferon lambda 3, are associated with significant differences in response to the treatment. This finding, originally reported in Nature, showed that genotype 1 hepatitis C patients carrying certain genetic variant alleles near the IL28B gene are more likely to achieve sustained virological response after the treatment than others. A later report from Nature demonstrated that the same genetic variants are also associated with the natural clearance of the genotype 1 hepatitis C virus.
We guarantee the quality .we also welcome your inspection or the third party inspection. We are manufacturer of the world famous Brand.And we also have our own Brand.
Tel:86-311-87775677
Fax: 86-311-87775277
Cheryl
Contact us if you need more details on Peginterferon Alfa-2b. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Injection、Medicine. If these products fail to match your need, please contact us and we would like to provide relevant information.
1,Product name:Peginterferon alfa-2b-100mcg/180mcg
2.Specification:100mcg/180mcg
3.Package:1vials +1amp+ syringe/box
4.Shelf life:36 months
5.Standard: GMP
6. Registration documents and samples can be provided.
7. Good quality and competitive price.
It has been approved as treatment for melanoma with nodal involvement after surgical resection in April 2011.
PEG-interferon alpha is a pegylated interferon composed of 165 amino acids. The PEG (polyethylene glycol) protects the molecule from proteolytic breakdown and increases the biological half-life of the interferon protein.
It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.
Mechanism of action
One of the major mechanisms of PEG-interferon alpha-2b utilizes the JAK-STAT signaling pathway. The basic mechanism works such that PEG-interferon alpha-2b will bind to its receptor, interferon-alpha receptor 1 and 2 (IFNAR1/2). Upon ligand binding the Tyk2 protein associated with IFNAR1 is phosphorylated which in turn phosphorylates Jak1 associated with IFNAR2. This kinase continues its signal transduction by phosphorylation of signal transducer and activator of transcription (STAT) 1 and 2 via Jak 1 and Tyk2 respectively. The phosphorylated STATs then dissociate from the receptor heterodimer and form an interferon transcription factor with p48 and IRF9 to form the interferon stimulate transcription factor-3 (ISGF3). This transcription factor then translocates to the nucleus where it will transcribe several genes involved in cell cycle control, cell differentiation, apoptosis, and immune response.
PEG-interferon alpha-2b acts as a multifunctional immunoregulatory cytokine by transcribing several genes, including interleukin 4 (IL4). This cytokine is responsible for inducing T helper cells to become type 2 helper T cells. This ultimately results in the stimulation of B cells to proliferate and increase their antibody production. This ultimately allows for an immune response, as the B cells will help to signal the immune system that a foreign antigen is present.
Another major mechanism of type I interferon alpha (IFNα) is to stimulate apoptosis in malignant cell lines. Previous studies have shown that IFNα can cause cell cycle arrest in U266, Daudi, and Rhek-1 cell lines.
A follow-up study researched to determine if the caspases were involved in the apoptosis seen in the previous study as well as to determine the role of mitochondrial cytochrome c release. The study confirmed that there was cleavage of caspase-3, -8, and -9. All three of these cysteine proteases play an important role in the initiation and activation of the apoptotic cascade. Furthermore, it was shown that IFNα induced a loss in the mitochondrial membrane potential which resulted in the release of cytochrome c from the mitochondria. Follow-up research is currently being conducted to determine the upstream activators of the apoptotic pathway that are induced by IFNα
Host genetic factors influencing treatment response
For genotype 1 hepatitis C treated with pegylated interferon-alfa-2a or pegylated interferon-alfa-2b combined with ribavirin, it has been shown that genetic polymorphisms near the human IL28B gene, encoding interferon lambda 3, are associated with significant differences in response to the treatment. This finding, originally reported in Nature, showed that genotype 1 hepatitis C patients carrying certain genetic variant alleles near the IL28B gene are more likely to achieve sustained virological response after the treatment than others. A later report from Nature demonstrated that the same genetic variants are also associated with the natural clearance of the genotype 1 hepatitis C virus.
We guarantee the quality .we also welcome your inspection or the third party inspection. We are manufacturer of the world famous Brand.And we also have our own Brand.
Tel:86-311-87775677
Fax: 86-311-87775277
Cheryl
Contact us if you need more details on Peginterferon Alfa-2b. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Injection、Medicine. If these products fail to match your need, please contact us and we would like to provide relevant information.
Product Categories : Pharmaceutical Products for Human > Others Pharmaceutical Products for Human
Premium Related Products
Other Products
Hot Products
Cefalotin Sodium for InjectionVitamin B1+B6+B12 InjectionGrape Seed and Vitamin E Soft CapsuleVitamin C Effervescent Tablets with GMP CertificationRed Soft Isotretinoin for Anti AcneAmbroxol Hydrochloride for InjectionEsomeprazole for InjectionAmpicloxaxillin for Injection 500mg100g Black Skin Whitening GlutathioneParacetamol InfusionAnti-Hair Loss Minoxidil InjectionEle Anti-Aging Collagen Filler InjectionSkin Whitening Glutathione Injection100g #High Quality Factory Supply#Lecithin Injection 250mg, Lipolysis for S. C., Ppc Phosphatidylcholine Injection for Weight Lose, L-Carnitine Injection for Body SlimmingGlutathione for Injection 2700mg*Skin Whitening Glutathione Injection &Actd/Ctd Dossier of Glutathione Injection 300mg /600mg/900mg/1200mg/1500mg/2400mg/3000mg